NEWS SUMMARY: CELLNEX, NATURGY. Stock markets pause for a break European stock markets recovered after the strong corrections seen last Friday, fuelled by banks. Thus, in the STOXX 600 most sectors (16/20) ended with gains, led by Banks and Insurance vs. Pharma and Retail that were the worst performers. On the macro side, in the euro zone, August’s Sentix dropped significantly as opposed to expectations following the tariff agreement signed with the US to the worst level since April. In the US,...
2Q'25 vs. 2Q'24 Results Sales: € 978.0 M (+0.3% vs. +0.2% BS(e) and +0.4% consensus); EBITDA: € 807.0 M (+0.9% vs. +0.9% BS(e) and +1.0% consensus); Net Profit: € -66.0 M (€ -379.0 M in 1H'24); 1H'25 vs. 1H'24 Results Sales: € 1.942 Bn (+1.1% vs. +1.0% BS(e) and +1.1% consensus); EBITDA: € 1.605 Bn (+1.7% vs. +1.7% BS(e) and +1.8% consensus); Net Profit: € -115.0 M (€ -418.0 M in 1H'24);
Rdos. 2T'25 vs 2T'24: Ventas: 978,0 M euros (+0,3% vs +0,2% BS(e) y +0,4% consenso); EBITDA: 807,0 M euros (+0,9% vs +0,9% BS(e) y +1,0% consenso); BDI: -66,0 M euros (-379,0 M euros en 1S'24). Rdos. 1S'25 vs 1S'24: Ventas: 1.942 M euros (+1,1% vs +1,0% BS(e) y +1,1% consenso); EBITDA: 1.605 M euros (+1,7% vs +1,7% BS(e) y +1,8% consenso); BDI: -115,0 M euros (-418,0 M euros en 1S'24).
NEWS SUMMARY: CELLNEX, IBERDROLA, REDEIA, SANTANDER. Trade matters put Europe in the red once again European stock markets fell due to trade matters. After the 01 August deadline passed, a 35% tariff was placed on Canada, 50% on Brazil, 25% on India, 20% on Taiwan and 39% on Switzerland, with another 69 trade partners facing tariffs between 10-41% if new agreements are not reached. As for Mexico, the country will continue to have a 25% tariff due to fentanyl, 25% on automobiles and 50% on steel...
COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: CELLNEX, IBERDROLA, REDEIA, SANTANDER. EUROPA: AB INBEV, AXA, BAYER. Incluido en el informe diario de hoy, y durante toda la campaña de resultados, incorporamos al final una presentación con los resultados destacados en positivo y negativo y previews de Rdos. 2T’25 que se publicarán en España y Europa en los próximos días. Europa vuelve a pérdidas por el tema comercial Cesiones en las bolsas europeas por el tema comercial. Tas vencer el deadline de...
2Q'25 vs. 2Q'24: NII: € 2.636 Bn (-5.6% vs. -6.1% BS(e) and -6.1% consensus); Total Revenues: € 4.030 Bn (-4.2% vs. -4.5% BS(e) and -5.6% consensus); Operating Income: € 2.431 Bn (-9.5% vs. -9.9% BS(e) and -11.7% consensus); Pre-AT1 Net Profit: € 1.482 Bn (-11.3% vs. -12.2% BS(e) and -18.8% consensus). 2Q'25 vs. 1Q'25: NII: € 2.636 Bn (-0.4% vs. -1% BS(e) and -1% consensus); Total Revenues: € 4.030 Bn (+0.5% vs. +0.1% BS(e) and -1.1% consensus); Operating Income: € 2.431 Bn (+0% vs. -0.5% BS(e) ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.